Azemiglitazone

Azemiglitazone (MSDC-0602) is a novel insulin sensitizer designed to retain the effect of thiazolidinediones on mitochondrial pyruvate carriers with limited PPAR-gamma binding. It is hoped to have fewer adverse effects than the thiazolidinediones and is being developed by Cirius Therapeutics for type 2 diabetes and non-alcoholic fatty liver disease.^[1][2][3] It is formulated as its potassium salt, azemiglitazone potassium (MSDC-0602K).^{[citation needed]}

Azemiglitazone

Clinical data
Other names	Azemiglitazone potassium; MSDC-0602; MSDC-0602K
Legal status
Legal status	Investigational
Identifiers
IUPAC name 5-[[4-[2-(3-Methoxyphenyl)-2-oxoethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
CAS Number	1133819-87-0
PubChem CID	25230266
DrugBank	DB16028
ChemSpider	32698412
UNII	81MXZ6QOBM
ChEMBL	ChEMBL4291468
Chemical and physical data
Formula	C19H17NO5S
Molar mass	371.41 g·mol−1
3D model (JSmol)	Interactive image
SMILES COC1=CC=CC(=C1)C(=O)COC2=CC=C(C=C2)CC3C(=O)NC(=O)S3
InChI InChI=1S/C19H17NO5S/c1-24-15-4-2-3-13(10-15)16(21)11-25-14-7-5-12(6-8-14)9-17-18(22)20-19(23)26-17/h2-8,10,17H,9,11H2,1H3,(H,20,22,23) Key:YAUMOGALQJYOJQ-UHFFFAOYSA-N